{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:14:30Z","timestamp":1768292070641,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bmcl.2021.127815","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T22:33:07Z","timestamp":1611268387000},"page":"127815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A new 1-nitro-9-aminoacridine derivative targeting yeast topoisomerase II able to overcome fluconazole-resistance"],"prefix":"10.1016","volume":"35","author":[{"given":"Kamila","family":"Rz\u0105d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Paluszkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmcl.2021.127815_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/47.1.1","article-title":"Acridine-a neglected antibacterial chromophore","volume":"47","author":"Wainwright","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.bmcl.2021.127815_b0010","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1039\/C8MD00384J","article-title":"Medicinal chemistry of acridine and its analogues","volume":"9","author":"Prasher","year":"2018","journal-title":"Med Chem Comm"},{"issue":"7","key":"10.1016\/j.bmcl.2021.127815_b0015","doi-asserted-by":"crossref","first-page":"pii: E1480","DOI":"10.3390\/molecules25071480","article-title":"\u2018Acridines\u2019 as new horizons in antifungal treatment","volume":"25","author":"Gabriel","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2021.127815_b0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejps.2015.04.023","article-title":"Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds","volume":"76","author":"Jano\u010dkov\u00e1","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"10.1016\/j.bmcl.2021.127815_b0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/13543776.2014.902052","article-title":"Acridine and its derivatives: a patent review (2009\u20132013)","volume":"24","author":"Zhang","year":"2014","journal-title":"Expert Opin Ther Pat"},{"issue":"12","key":"10.1016\/j.bmcl.2021.127815_b0030","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1128\/AEM.00748-13","article-title":"Imidazoacridinone derivatives as efficient sensitizers in photoantimicrobial chemotherapy","volume":"79","author":"Taraszkiewicz","year":"2013","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.bmcl.2021.127815_b0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/md8010091","article-title":"Antimicrobial photodynamic therapy: study of bacterial recovery viability and potential development of resistance after treatment","volume":"8","author":"Tavares","year":"2010","journal-title":"Mar Drugs"},{"key":"10.1016\/j.bmcl.2021.127815_b0040","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu Rev Biochem"},{"issue":"23","key":"10.1016\/j.bmcl.2021.127815_b0045","first-page":"8400","article-title":"Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug","volume":"63","author":"Li","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.bmcl.2021.127815_b0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/med.21364","article-title":"Cutts SM mitoxantrone, more than just another topoisomerase II poison","volume":"36","author":"Evison","year":"2016","journal-title":"Med Res Rev"},{"issue":"4","key":"10.1016\/j.bmcl.2021.127815_b0055","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/mol.104.000703","article-title":"The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties","volume":"66","author":"Lemke","year":"2004","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.bmcl.2021.127815_b0060","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.bbrc.2014.03.029","article-title":"Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison","volume":"446","author":"Godbole","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.bmcl.2021.127815_b0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmcl.2021.127815_b0070","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1038\/ncomms10048","article-title":"Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin","volume":"6","author":"Chan","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bmcl.2021.127815_b0075","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1073\/pnas.81.9.2616","article-title":"DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication","volume":"81","author":"DiNardo","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.bmcl.2021.127815_b0080","first-page":"159","article-title":"DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage","volume":"9","author":"Holm","year":"1989","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.bmcl.2021.127815_b0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/13693780903114934","article-title":"In vitro effect of DNA topoisomerase inhibitors on Candida albicans","volume":"48","author":"Kwok","year":"2010","journal-title":"Med Mycol"},{"issue":"6","key":"10.1016\/j.bmcl.2021.127815_b0090","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1128\/AAC.46.6.1785-1792.2002","article-title":"Antifungal activity of eupolauridine and its action on DNA topoisomerases","volume":"46","author":"Khan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.bmcl.2021.127815_b0095","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.12.4.583","article-title":"Antifungal activities of antineoplastic agents: saccharomyces cerevisiae as a model system to study drug action","volume":"12","author":"Cardenas","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bmcl.2021.127815_b0100","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1128\/AAC.36.12.2778","article-title":"DNA topoisomerases from pathogenic fungi: Targets for the discovery of antifungal drugs","volume":"36","author":"Shen","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"18","key":"10.1016\/j.bmcl.2021.127815_b0105","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.lfs.2005.03.020","article-title":"Comparative analysis of mutagenic potency of 1-nitro-acridine derivatives","volume":"77","author":"Narayanan","year":"2005","journal-title":"Life Sci"},{"issue":"14)","key":"10.1016\/j.bmcl.2021.127815_b0110","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.lfs.2006.03.043","article-title":"Pre-clinical toxicology and pathology of 9-(2\u2032-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), a novel anti-cancer agent in male Beagle dogs","volume":"79","author":"Ashok","year":"2006","journal-title":"Life Sci"},{"issue":"87\u201394","key":"10.1016\/j.bmcl.2021.127815_b0115","first-page":"34","article-title":"Pre-clinical toxicological evaluation of a putative prostate cancer specific 1-nitroacridine derivative in rodents","volume":"18","author":"Ashok","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"1)","key":"10.1016\/j.bmcl.2021.127815_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/tx000081c","article-title":"Products of metabolic activation of the antitumor drug ledakrin (Nitracrine) in vitro","volume":"14","author":"Gorlewska","year":"2001","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"10.1016\/j.bmcl.2021.127815_b0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0009-2797(83)90094-7","article-title":"The mode of action of cytotoxic and antitumor 1-nitroacridines. III. In vivo interstrand cross-linking of DNA of mammalian or bacterial cells by 1-nitroacridines","volume":"43","author":"Konopa","year":"1983","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.bmcl.2021.127815_b0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcp.2012.03.013","article-title":"Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells","volume":"84","author":"Wi\u015bniewska","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.bmcl.2021.127815_b0135","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0306-3623(94)00143-B","article-title":"Nitracrine and its congeners-an overview","volume":"26","author":"Gniazdowski","year":"1995","journal-title":"Gen Pharmacol"},{"issue":"10","key":"10.1016\/j.bmcl.2021.127815_b0140","first-page":"4289","article-title":"Cytotoxic and antitumor activity of 1-nitroacridines as an aftereffect of their interstrand DNA cross-linking","volume":"44","author":"Pawlak","year":"1984","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.bmcl.2021.127815_b0145","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1016\/0006-2952(89)90691-6","article-title":"Induction of DNA-protein crosslinks by antitumor 1-nitro-9-aminoacridines in L1210 leukemia cells","volume":"38","author":"Woynarowski","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2021.127815_b0150","doi-asserted-by":"crossref","unstructured":"Tadi K, Ashok BT, Chen Y, Banerjee D, Wysocka-Skrzela B, Konopa J, Darzynkiewicz Z, Tiwari RK. Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer. Cancer Biol Ther. 2007 6(10): 1632-1637. Erratum in: Cancer Biol Ther. 2008 7(3): 479. doi: 10.4161\/cbt.6.10.4790.","DOI":"10.4161\/cbt.6.10.4790"},{"issue":"9","key":"10.1016\/j.bmcl.2021.127815_b0155","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.bcp.2009.12.012","article-title":"Antitumor 1-nitroacridine derivative C-1748, induces apoptosis, necrosis or senescence in human colon carcinoma HCT8 and HT29 cells","volume":"79","author":"Augustin","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2021.127815_b0160","unstructured":"Konopa J, Wysocka-Skrzela B, Tiwari RK. 9-Alkilamino-1-nitroacridine derivatives, European patent, 01910914.9-2101-US0105199 (1981), American patent, 6.589.961 B233."},{"key":"10.1016\/j.bmcl.2021.127815_b0165","first-page":"317","article-title":"Research on tumor-inhibiting compounds. Part LXXVI. Reactions of 1-nitro-9-aminoacridine derivatives, new antitumor agents, with nucleophiles","volume":"60","author":"Wysocka-Skrzela","year":"1986","journal-title":"Pol J Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2021.127815_b0170","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/EC.00031-12","article-title":"Hypoxia and fungal pathogenesis: to air or not to air?","volume":"11","author":"Grahl","year":"2012","journal-title":"Eukaryot Cell"},{"issue":"4","key":"10.1016\/j.bmcl.2021.127815_b0175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/13543776.2011.560570","article-title":"Acridine derivatives: a patent review (2009\u20132010)","volume":"21","author":"Kaur","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2021.127815_b0180","first-page":"237","article-title":"Ledakrin \u2013 anticancerous medicine 1-nitro-9-(3-dimethylaminopropyloamino)-acridine-2HCl-H2O","volume":"8","author":"Led\u00f3chowski","year":"1976","journal-title":"Mater Med Pol"},{"key":"10.1016\/j.bmcl.2021.127815_b0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0045-2068(90)90042-4","article-title":"Stereochemistry of the michael addition of lysine derivatives to \u03b1-methylene-\u03b3-butyrolactones","volume":"18","author":"Talaga","year":"1990","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2021.127815_b0190","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1021\/jo00349a028","article-title":"Esterification of N-protected.alpha.-amino acids with alcohol\/carbodiimide\/4-(dimethylamino)pyridine. Racemization of aspartic and glutamic acid derivatives","volume":"47","author":"Dhaon","year":"1982","journal-title":"J Org Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2021.127815_b0195","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1021\/acsmedchemlett.7b00119","article-title":"Branched Peptides: Acridine and Boronic Acid Derivatives as Antimicrobial Agents","volume":"8","author":"Wynn","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2021.127815_b0200","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1128\/AAC.42.12.3065","article-title":"Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains","volume":"42","author":"Franz","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2021.127815_b0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1439-0507.1999.00498.x","article-title":"Molecular aspects of fluconazole resistance development in Candida albicans","volume":"42","author":"Franz","year":"1999","journal-title":"Mycoses"},{"issue":"1","key":"10.1016\/j.bmcl.2021.127815_b0210","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/jb.108.1.320-327.1971","article-title":"Antibacterial nitroacridine, Nitroakridin 3582: effects on bacterial growth and macromolecular biosynthesis in vivo","volume":"108","author":"Wolfe","year":"1971","journal-title":"J Bacteriol"},{"issue":"1","key":"10.1016\/j.bmcl.2021.127815_b0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0223-5234(90)90166-Z","article-title":"Some new 1-nitro acridine derivatives as antimicrobial agents","volume":"25","author":"Ngadi","year":"1990","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2021.127815_b0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/21501203.2017.1421592","article-title":"Fungicidal versus fungistatic therapy of invasive Candida infection in non-neutropenic adults: a meta-analysis","volume":"9","author":"Kumar","year":"2018","journal-title":"Mycology"},{"issue":"34","key":"10.1016\/j.bmcl.2021.127815_b0225","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1021\/acs.jafc.5b02728","article-title":"Genesis of azole antifungal resistance from agriculture to clinical settings","volume":"63","author":"Azevedo","year":"2015","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.bmcl.2021.127815_b0230","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1099\/13500872-140-7-1505","article-title":"Pathogenicity determinants of Candida albicans: potential targets for immunotherapy?","volume":"140","author":"Matthews","year":"1994","journal-title":"Microbiology"},{"key":"10.1016\/j.bmcl.2021.127815_b0235","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1462-5822.2005.00616.x","article-title":"Contributions of hyphae and hyphae-co-regulated genes to Candida albicans virulence","volume":"7","author":"Kumamoto","year":"2005","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.bmcl.2021.127815_b0240","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1586\/eri.11.152","article-title":"Candida albicans dimorphism as a therapeutic target","volume":"10","author":"Jacobsen","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.bmcl.2021.127815_b0245","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/nrg948","article-title":"Candida albicans: a molecular revolution built on lessons from budding yeast","volume":"12","author":"Berman","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.bmcl.2021.127815_b0250","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/EC.2.5.1053-1060.2003","article-title":"Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection","volume":"2","author":"Saville","year":"2003","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.bmcl.2021.127815_b0255","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0092-8674(00)80358-X","article-title":"Nonfilamentous C. albicans mutants are avirulent","author":"Lo","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2021.127815_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002585","article-title":"Mitchell AP. Fungal biofilms","volume":"8","author":"Fanning","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmcl.2021.127815_b0265","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrmicro2475","article-title":"Genetic control of Candida albicans biofilm development","volume":"9","author":"Finkel","year":"2011","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.bmcl.2021.127815_b0270","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/jam.13030","article-title":"Bacillomycin D and its combination with amphotericin B: Promising antifungal compounds with powerful antibiofilm activity and wound-healing potency","volume":"120","author":"Tabbene","year":"2016","journal-title":"J Appl Microbiol"},{"issue":"12","key":"10.1016\/j.bmcl.2021.127815_b0275","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1128\/AAC.03083-14","article-title":"Quinacrine inhibits Candida albicans growth and filamentation at neutral pH","volume":"58","author":"Kulkarny","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.bmcl.2021.127815_b0280","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/jam.14381","article-title":"A new acridone with antifungal properties against Candida spp. and dermatophytes, and antibiofilm activity against C. albicans","volume":"127","author":"de Oliveira","year":"2019","journal-title":"J Appl Microbiol"},{"issue":"3","key":"10.1016\/j.bmcl.2021.127815_b0285","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/14756366.2012.658785","article-title":"Topoisomerase as target for antibacterial and anticancer drug discovery","volume":"28","author":"Kathiravan","year":"2013","journal-title":"J Enzyme Inhibit Med Chem"},{"key":"10.1016\/j.bmcl.2021.127815_b0290","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/genetics\/152.1.167","article-title":"Topoisomerase I is essential in Cryptococcus neoformans: role in pathobiology and as an antifungal target","volume":"152","author":"Del Poeta","year":"1999","journal-title":"Genetics"},{"key":"10.1016\/j.bmcl.2021.127815_b0295","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1099\/00221287-143-2-377","article-title":"The topoisomerase I gene from Candida albicans","volume":"143","author":"Jiang","year":"1997","journal-title":"Microbiology"},{"key":"10.1016\/j.bmcl.2021.127815_b0300","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1054-3589(08)61140-0","article-title":"DNA topoisomerase inhibitors as antifungal agents","volume":"29","author":"Shen","year":"1994","journal-title":"Adv Pharmacol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2100041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2100041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:38:09Z","timestamp":1760773089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2100041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":60,"alternative-id":["S0960894X2100041X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.127815","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new 1-nitro-9-aminoacridine derivative targeting yeast topoisomerase II able to overcome fluconazole-resistance","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.127815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"127815"}}